GlaxoSmithKline has announced that it will invest approximately £200 million in UK manufacturing sites, including a new manufacturing facility in Ware for the Relvar Ellipta dry powder inhaler. The DPI was approved in Europe in November 2013 and in the US (as Breo Ellipta) in May 2013.
The Ware site already employs more approximately 800 people, with 500 of those dedicated to development and manufacturing of respiratory products. According to GSK, the site currently produces over 35 million units of respiratory products that are shipped to 120 countries. Relvar Ellipta was developed at Ware.
GSK said that it also favors Ware as the site of a new center for pharmaceutical manufacturing innovation that it says will be “dedicated to harnessing innovative technologies with the potential to transform both the way medicines are made and the company’s supply chain.”
Read the GSK press release.
